The medicine of the future is personalized, precise, and holistic. One of the most promising approaches of this new era is apheresis therapy, which selectively removes unwanted substances from the blood to treat inflammation, lipid disorders, and even chronic infection-related conditions.
In the following sections, we take a closer look at current scientific findings that highlight the potential of apheresis in various medical fields.
Lipoprotein apheresis (LA) has established itself as a highly effective therapy for treating familial hypercholesterolemia and lipoprotein(a)-hyperlipidemia.
Despite being an invasive procedure, it demonstrates:
“Can apheresis do more than just lower cholesterol?”
Indeed, studies suggest that the benefits of LA extend beyond mere lipid reduction. It also removes pro-inflammatory and pro-atherogenic factors, leading to a more comprehensive reduction of cardiovascular risk.
Thus, lipoprotein apheresis stands at the center of a modern treatment strategy that combines effectiveness and safety.
Plastic pollution is no longer just an environmental issue. Microplastics have become a serious threat to food systems and human health.
“How strongly do microplastics affect our blood, our cells – and ultimately our well-being?”
Studies show that:
The findings regarding nanoplastics (NPs) are particularly alarming – they indicate chronic toxicity that affects the liver, heart, and nervous system.
Lyme disease, caused by Borrelia burgdorferi, is a complex bacterial infection that can produce a wide range of symptoms. Recent research indicates a close connection between lipid metabolism and disease progression.
Scientific findings show that:
These insights lead to an exciting hypothesis:
Apheresis could help modulate inflammation and bacterial persistence through lipid reduction.
Early pilot studies support this innovative concept – further research is currently underway.
Many patients continue to struggle with persistent symptoms following a SARS-CoV-2 infection, known as Post-COVID or Long-COVID. These include:
This symptom pattern is strikingly similar to Chronic Fatigue Syndrome (CFS).
“What if the key to recovery lies within the blood itself?”
Current studies have detected elevated autoantibodies against neurotransmitter receptors in Long-COVID and CFS patients.
Extracorporeal apheresis offers a new therapeutic approach by:
Source: Felix Scholkmann, Antonietta M. Gatti
Double Filtration Plasmapheresis (DFPP) is an advanced blood purification method closely associated with INUSpherese® technology.
A recent study examined which micro- and nanoparticles remain in the eluate after treatment.
“What remains once the blood has been cleansed?”
Using field emission scanning electron microscopy (FE-SEM-EDX), researchers identified particles containing:
These findings emphasize that DFPP technology can be valuable not only therapeutically but also diagnostically.
Chronic inflammation is considered the silent driver of many diseases – from autoimmune disorders to neurodegenerative conditions.
“Can we stop inflammation before it becomes disease?”
INUSpherese® therapy addresses this question by:
The studies presented here clearly demonstrate that apheresis is far more than a classic detoxification method.
It represents a precise, scientifically grounded approach that harmonizes metabolism, immune function, and cellular health.
With technologies like INUSpherese®, medicine is becoming increasingly individualized, aiming to treat diseases holistically – before they become chronic.
“Precision medicine begins where therapy is tailored to the biochemistry of the individual.”